CDIO Cardio Diagnostics Holdings, Inc.: Rentabilitas operasi

Cardio Diagnostics (CDIO) is in a stage of technological growth, scaling AI services for blood analysis independently of macroeconomic cycles. Genetic tests are generating steady B2B demand, establishing a foundation for future free cash flow. However, current revenue is limited by the pace of system implementation in clinics. The operating margin trajectory demonstrates business efficiency, and this metric settled at -42649.80.
CDIO (Cardio Diagnostics Holdings Inc.): rincian analitis lan laporan miturut indikator

Operating margin measures the share of profit from core operations before interest and taxes, demonstrating cost management efficiency and the fundamental resilience of the business. Analyzing this operating profitability metric allows investors to understand how successfully Cardio Diagnostics (CDIO) monetizes its genetic tests and epigenetic research for the prevention of cardiological risks amid the diversification of medical revenues.